Apremilast
18 interactions 44 cited referencesApremilast is used to treat psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin). It is also used to treat moderate to severe plaque psoriasis (skin disease in which red, scaly patches form on some areas of the body) in people who may benefit from medications or phototherapy (a t… Read the full Apremilast drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Contraindicated
Apremilast Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects DetailsMajor
Apremilast Apalutamide Erleada Reduced apremilast exposure and an reduced efficacy of apremilast Details Apremilast Carbamazepine Carbatrol Reduced apremilast exposure and an reduced efficacy of apremilast Details Apremilast Encorafenib Braftovi Reduced apremilast exposure and an reduced efficacy of apremilast Details Apremilast Enzalutamide Xtandi Reduced apremilast exposure and an reduced efficacy of apremilast Details Apremilast Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Apremilast Fosphenytoin Cerebyx Reduced apremilast exposure and an reduced efficacy of apremilast Details Apremilast Ivosidenib Tibsovo Reduced apremilast exposure and an reduced efficacy of apremilast Details Apremilast Lumacaftor Reduced apremilast exposure and an reduced efficacy of apremilast Details Apremilast Mitotane Lysodren Reduced apremilast exposure and an reduced efficacy of apremilast Details Apremilast Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Apremilast Phenytoin Dilantin Reduced apremilast exposure and an reduced efficacy of apremilast Details Apremilast Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Apremilast Rifampin Rifadin Reduced apremilast exposure and an reduced efficacy of apremilast Details Apremilast Rifapentine Priftin Reduced apremilast exposure and an reduced efficacy of apremilast Details Apremilast St John's Wort Reduced apremilast exposure and an reduced efficacy of apremilast DetailsModerate
Apremilast Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Apremilast Kratom Increased CYP3A substrate exposure DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist